TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19565156
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy agents
Study: 14666399
Drug: Paroxetine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (40 mg daily)
Study: 9209013
Drug: Beta-carotene and
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene and other compounds
Study: 3501252
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg/kg body weight)
Study: 26331782
Drug: Drug-coated scoring
Normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated scoring balloon (SB)
Study: 23543483
Drug: Piribedil up
Normalized name: piribedil
DrugBank: Piribedil (DB12478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piribedil up to 300 mg per day (n = 19)
Study: 10970993
Drug: Dietary beta-carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary beta-carotene supplementation (60 mg daily for 3 weeks)
Study: 22924071
Drug: Inhaled budesonide/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide/formoterol
Study: 22924071
Drug: Inhaled fluticasone/salmeterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone/salmeterol
Study: 21114387
Drug: Nonechinocandins (comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonechinocandins (comparator drug)
Study: 18534669
Drug: Radiotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy combined with three courses of cisplatin (50 mg/m(2)), epirubicin (60 mg/m(2)), and cyclophosphamide (500 mg/m(2)) (Group B, n=84)
Study: 10535718
Drug: enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 10 mg
Study: 1745340
Drug: Prednisone (varied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (varied dosages from 0.15 mg/kg to 0.75 mg/kg)
Study: 6136489
Drug: lopirazepam (tranquillizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopirazepam (tranquillizing agent)
Study: 23228119
Drug: 0.025% capsaicin
Normalized name: CAPSAICIN 2.5 mg in 10 g TOPICAL PATCH [0.025% Capsaicin Patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% capsaicin gel
Study: 21823969
Drug: Valsartan/HCTZ combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/HCTZ combination therapy administered at bedtime
Study: 21823969
Drug: Valsartan/HCTZ combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/HCTZ combination therapy administered upon awakening
Study: 21823969
Drug: Both treatment-time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment-time groups (bedtime and upon awakening)
Study: 21823969
Drug: Bedtime combination
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime combination treatment
Study: 15526557
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (200 mg/daily)
Study: 15526557
Drug: Oral progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral progesterone (200 mg/daily)
Study: 2272708
Drug: Calcium gluconate
Normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium gluconate therapy
Study: 2272708
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of calcium and nifedipine
Study: 7419561
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without antithrombotic therapy
Study: 31779683
Drug: Adapted Mindfulness-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted Mindfulness-Based Childbirth and Parenting (MBCP) program + treatment as usual (TAU)
Study: 24253250
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg/daily)
Study: 20881400
Drug: Simultaneous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous treatment for quitting both alcohol and tobacco
Study: 20881400
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (help to quit smoking after 6 months)
Study: 19016404
Drug: SHR‐5 extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR‐5 extract (576 mg extract/day)
Study: 7234826
Drug: Placebo (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (four tablets daily)
Study: 15460213
Drug: Standardized European
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized European mistletoe extract (Viscum album L., Iscador) given in addition to conventional adjuvant oncologic therapy for at least three months.
Study: 15460213
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy only (control group).
Study: 15460213
Drug: Standardized European
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized European mistletoe extract (Viscum album L., Iscador) given in addition to conventional adjuvant oncologic therapy.
Study: 11585017
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives (OCs)
Study: 9613295
Drug: Propofol (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1, 2, 3, 4, 5 or 6 micrograms.ml‐1) and Sufentanil (0.1, 0.2, 0.3, 0.5 or 1.0 ng.ml‐1) target concentrations for induction of anaesthesia
Study: 26939326
Drug: Encircling needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encircling needling combined with physical factor therapy
Study: 26939326
Drug: Conventional nursing,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional nursing, ultrasonic wave and short-wave ultraviolet therapy (Control group)
Study: 10361566
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (up to 12 sessions)
Study: 8542914
Drug: Subcutaneous sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous sumatriptan 6 mg administered by an auto‐injector
Study: 8542914
Drug: Usual acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual acute migraine treatments
Study: 2193840
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg frusemide/2.5 mg amiloride
Study: 2361567
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg frusemide
Study: 531993
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg) three times daily
Study: 531993
Drug: Dipyridamole (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (75 mg) three times daily
Study: 531993
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg) plus Dipyridamole (75 mg) three times daily
Study: 31867908
Drug: Tongdu Tiaoshen
Normalized name: MENTHOL 3 g TRANSDERMAL PATCH [TIANHE GUBEN YAOSHEN TIE GAO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongdu Tiaoshen needling treatment
Study: 31867908
Drug: Conventional medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional medicines and conventional needling treatment
Study: 23689595
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg vitamin C/day
Study: 23689595
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg vitamin C/day
Study: 23689595
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (unspecified dose)
Study: 17716335
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg GH/m(2)/day (group A, n = 34)
Study: 15100514
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of WBC scan and BM scan
Study: 12714834
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin with aspirin
Study: 9839101
Drug: Isradipine (2.5‐5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (2.5‐5 mg twice a day)
Study: 9839101
Drug: Hydrochlorothiazide (12.5‐25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (12.5‐25 mg twice a day)
Study: 2815969
Drug: Inactivated whole‐virion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated whole‐virion trivalent influenza vaccine (A/Leningrad/360/86(H3N2), A/Taiwan/5/87 and B/Ann Arbor/1/86)
Study: 1173059
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of intravenous propranolol
Study: 1173059
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of intravenous tolamolol
Study: 1173059
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of intravenous tolamolol
Study: 2750683
Drug: Antimicrobial agents
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial agents that preserved the microflora and contained no NMTT moiety
Study: 352631
Drug: Halcinonide-neomycin-amphotericin ointment
Normalized name: halcinonide / neomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halcinonide-neomycin-amphotericin ointment
Study: 29739385
Drug: Augmented physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented physical education program (270 minutes of weekly physical education)
Study: 29931852
Drug: DEX (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX (1 μg/kg before induction and 0.5 μg/(kg·h) maintenance)
Study: 24867834
Drug: Onabotulinumtoxin A
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Onabotulinumtoxin A injection
Study: 22659759
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% ketamine cream
Study: 16092677
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1% (10 ml)
Study: 29053118
Drug: Nooklerin (deanoli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nooklerin (deanoli aceglumas) administered as add-on treatment at a daily dose of 1000 mg for 30 days
Study: 29053118
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving standard psychopharmacological treatment without nooklerin
Study: 23937405
Drug: Adper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt L‐Pop (AP), active application (APA)
Study: 23937405
Drug: Adper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt L‐Pop (AP), passive application (APP)
Study: 22935960
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-Acetylcysteine (NAC) 1,200 mg
Study: 18952228
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (450 mg/d in 3 doses for 6 days)
Study: 18952228
Drug: Placebo (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5% dextrose, identical administration)
Study: 17615450
Drug: Education program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education program for safe drug use (1.5 hours, once a week for 3 weeks)
Study: 15097245
Drug: telmisartan 20
Normalized name: telmisartan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: telmisartan 20 mg
Study: 15097245
Drug: hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydrochlorothiazide (HCTZ) 12.5 mg
Study: 11579944
Drug: Cabergoline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (0.5 mg twice weekly for 12 weeks)
Study: 11579944
Drug: Bromocriptine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2.5 mg or 5 mg twice daily for 12 weeks)
Study: 3122919
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy conducted by general practitioners in group sessions once a week for eight weeks, accompanied by galvanic skin resistance biofeedback.
Study: 3122919
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no relaxation therapy).
Study: 3122919
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy conducted by general practitioners.
Study: 30516328
Drug: Rapid induction
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid induction chemotherapy (COJEC)
Study: 2060540
Drug: Nimodipine 30
Normalized name: nimodipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 30 mg t.i.d. for 4 days
Study: 2060540
Drug: Nimodipine 60
Normalized name: nimodipine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 60 mg t.i.d. for 4 days
Study: 31028610
Drug: High-dose epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose epirubicin 150 mg/m2 and cyclophosphamide 1500 mg/m2 with filgrastim support every 3 weeks for 3 cycles (HDEC)
Study: 31028610
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose epirubicin 75 mg/m2 and cyclophosphamide 750 mg/m2 every 3 weeks for 6 cycles (SDEC)
Study: 26075488
Drug: d‐MPH (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐MPH (0.15 mg/kg) with ethanol (0.6 g/kg)
Study: 26075488
Drug: dl‐MPH (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl‐MPH (0.3 mg/kg) with ethanol (0.6 g/kg)
Study: 26075488
Drug: d‐MPH (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐MPH (0.15 mg/kg)
Study: 16772451
Drug: IV Fe+EPO
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Fe+EPO [2 mg IV sucrose Fe/(kg.d) plus 2100 U EPO/(kg.wk)]
Study: 7957481
Drug: Active approach
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active approach (aggressive rehabilitation program at CPRC, 4-week program of daily physical therapy, occupational therapy, behavioral modification, and counseling)
Study: 2820672
Drug: Laxative regime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxative regime (sterculia, magnesium sulfate, mineral oil)
Study: 28420352
Drug: Telemonitoring intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemonitoring intervention (daily weight measurement using digital scale)
Study: 26200182
Drug: Gabapentin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (600 mg preoperatively followed by 200 mg every 8 h for 2 days)
Study: 17196055
Drug: Olanzapine (14.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (14.7 mg/day)
Study: 17196055
Drug: Risperidone (3.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (3.9 mg/day)
Study: 10893357
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide inhalation (20 parts per million for 30 min at 12‐h intervals until extubation)
Study: 9042260
Drug: ML-1 standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML-1 standardized mistletoe extract, 1 ng ML-1/kg BW, twice a week for 3 months, starting on day 1 post surgery
Study: 9042260
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without additional complementary treatment
Study: 9042260
Drug: ML-1 standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML-1 standardized mistletoe extract
Study: 2578724
Drug: Nimodipine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (120 mg daily)
Study: 2578724
Drug: Control (dextran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (dextran therapy alone)
Study: 29922605
Drug: SRM‐IV vestibular
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRM‐IV vestibular function diagnosis and treatment system
Study: 29922605
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of treatment drugs (alprostadil and safflower injection) with acclimatization training
Study: 17396118
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) ferric gluconate for eight consecutive hemodialysis sessions spanning 6 weeks with epoetin increased by 25%
Study: 15567810
Drug: midazolam 5
Normalized name: midazolam 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 5 mg
Study: 15567810
Drug: midazolam 10
Normalized name: midazolam 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 10 mg
Study: 12079935
Drug: 100 IU
Normalized name: Vitamin E 100 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 IU x kg(‐1) of heparin (group A)
Study: 12079935
Drug: 150 IU
Normalized name: Follitropin Beta 150 IU/0.5 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU x kg(‐1) of heparin (group B)
Study: 12079935
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of heparin
Study: 2252526
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins (0.4 g/kg/BW) for 1 week and once per week for 6 months
Study: 23024102
Drug: Oral chloral
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chloral hydrate (100 mg/kg)
Study: 16771816
Drug: FTY720 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 5 mg plus RDC
Study: 17198261
Drug: FTY720 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 2.5 mg plus FDC
Study: 7994791
Drug: Adriamycin (ADM)
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin (ADM) 50 mg/50 ml saline
Study: 7994791
Drug: Adriamycin (ADM)
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin (ADM) 50 mg/40 ml saline plus verapamil (VR) 25 mg/10 ml saline
Study: 2464184
Drug: Blood-isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood-isotonic saline solution
Study: 2464184
Drug: Nonionic contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonionic contrast media followed by saline solution
Study: 7816385
Drug: Stannous enhancement
Normalized name: Stannous chloride
DrugBank: Stannous chloride (DB11056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stannous enhancement method of preparation
Study: 22674529
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (docetaxel 60 mg/m(2) and carboplatin AUC = 5 for 2 cycles) plus concurrent radiation therapy (40 Gy) followed by surgery (CRS arm)
Study: 22674529
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by surgery (CS arm)
Study: 18090460
Drug: Levetiracetam (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (500 to 3000 mg/d)
Study: 9807979
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg three times daily
Study: 7695971
Drug: OND 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: OND 8 mg tablet
Study: 7695971
Drug: ALI 150
Normalized name: acetaminophen / phenyltoloxamine citrate Oral Tablet [Ali Flex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALI 150 mg i.v. injection followed by ALI 50 mg tablet
Study: 340182
Drug: Diflunisal, 375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal, 375 mg twice daily
Study: 340182
Drug: Oxyphenbutazone, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxyphenbutazone, 200 mg twice daily
Study: 20370794
Drug: fluvastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluvastatin 80 mg XL
Study: 19690081
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg NBI-6024
Study: 19690081
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg NBI-6024
Study: 19690081
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg NBI-6024
Study: 19690081
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (0.1 mg, 0.5 mg, 1.0 mg NBI-6024, and placebo)
Study: 9506192
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers (including long-acting dihydropyridines and nondihydropyridine agents)
Study: 9506192
Drug: Short-acting agents
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting agents (e.g., nifedipine)
Study: 8036828
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication at the time of vaccination
Study: 8036828
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of medication at the time of vaccination
Study: 23445320
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg·kg(‐1))
Study: 23445320
Drug: Bupivacaine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (2 mg·kg(‐1))
Study: 20130841
Drug: pioglitazone (15-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone (15-30 mg/day)
Study: 20130841
Drug: metformin (500-750
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin (500-750 mg/day)
Study: 15995024
Drug: 1 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/kg IVIG over 2 days
Study: 15995024
Drug: 0.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg IVIG over 5 days
Study: 15995024
Drug: 2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/kg IVIG administered over 2 days
Study: 15995024
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days treatment
Study: 12850889
Drug: Test drink
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drink with antioxidants (450 ml/day for 4 weeks)